Moss Vision is a company established in the United Kingdom, manufacturing superior IOLs and viscoelastics.

The main objective of Moss Vision is to give patients and practitioners high quality products to their level of satisfaction.

 ISO 9001:2000 and ISO 13485:2003 certified, the company Moss Vision is a symbol of the English tradition and quality.

For over 30 years, pfm Produkte für die Medizin AG has been one of Germany’s leading independent marketing and sales specialists for medical technology products in the fields of pathology/histology, OP/anaesthesia, infusion therapy and interventional technologies.

Pfm provides its customers with reliable products, top-quality information and individualised consulting, together with customised service solutions ranging from extending customer shopping baskets to application-specific CPTs and electronic order and information links.

pfm markets exclusive product ranges from leading manufacturers around the world, complementing them with its own innovative developments and additional products to produce user-specific product and solution packages for inpatient and outpatient treatment.

Comprehensive market know-how, long-standing personal customer contacts and R&D expertise geared to special solutions give pfm a solid market position and continued excellent prospects for further growth.

Using its own Group production companies, pfm manufactures standard products for OP use as well as specialised products for regional tumour therapy and interventional surgery in the fields of radiology and child/adult cardiology.

With its latest company acquisitions, pfm is expanding in the areas of development and the production of high-tech solutions for interventional implants, and is also expanding its sales network in the surgery-based sector.

Heidelberg Engineering is a high tech medical device company which designs, manufactures, and distributes diagnostic instruments for eye care professionals.  The company’s products are used around the world by ophthalmologists and optometrists to scan patients’ eyes for signs of disease and to assist in the management of patients found to have disease.  Early recognition of disease helps to delay and prevent the most common causes of blindness.

Typical diseases which can be recognized and tracked with our technology include glaucoma, age-related macular degeneration, diabetic retinopathy and macular edema associated with cataract surgery.

The company’s core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography and software image analysis.

Heidelberg Engineering is a privately held company, headquartered in Heidelberg, Germany. The company distributes its products through a network of wholly owned subsidiaries and distribution partners in most countries of the world.

For more information, please visit  www.heidelbergengineering.com

The Biotech group operates as Biotech Visioncare for the production and supply of Intraocular Lenses, and as Biotech Ophthalmics, it offers a range of Ophthalmic solutions. With its global presence and goodwill, the company develops and manufactures high quality, innovative ophthalmic surgical and eye care products that address a wide range of eye disorders.

Based in Ahmedabad, India, the company operates from a custom-built facility with advanced CNC machines, under a controlled clean room environment. Research and development activities for eyecare and the ophthalmic surgical business is aimed at enhancing lens implantation through technologically advanced delivery systems and new designs for intraocular lenses.

Biotech is focused on the growth and expansion of its core businesses.

Few of its assets include:

Biotech is one of the largest manufacturers of IOLs in the world, with a production capacity of over 1.5 million IOLs per annum. Biotech Vision Care has to its credit, the successful execution of supplying over 4,50,000 lenses, as a requirement for the Blindness Eradication Program, a Government of India undertaking.

Biotech е един от най-големите производители на вътреочни лещи в света, с производствен капазитет от 1.5 милиона вътреочни лещи на година. Biotech Visioncare на свой ред успешно доставя над 450 000 лещи във връзка с изискване по програма „Премахване на слепотата”, предприета от правителството на Индия.

In addition to the above, Biotech enjoys a major share in the domestic market, and sports a remarkable overseas network as well. The company currently exports its products to 60 countries including those in Europe, South America, the Middle East, North Africa, South-East Asia and the SAARC Nations.

"As manufacturers and exporters of Intraocular Lenses and patented technology in delivery sytems, we are integrating the world of vision with focussed development of ophthalmic surgical products."

Mehul Asnani, Chairman and CEO

Rapid Pathogen Screening (RPS), Inc. is a bio-technology company with a revolutionary assay platform known as Direct Sampling Micro-Filtration Technology. This proprietary technology enables RPS to develop, manufacture, and market rapid, easy-to-use, point-of-care diagnostic detection tests for infectious diseases and agents, inflammatory conditions, genetic markers, and select chemical warfare and bio-terrorism agents.

The company's first product, the RPS Adeno Detector^TM represents the first CLIA-waived, in-office device that physicians can use to determine the underlying source of infectious conjunctivitis (commonly known as pink eye).

Vision

RPS, Inc. strives to be recognized as the worldwide vanguard for Direct Sampling Micro-Filtration Assay (DSM-FA) technology and the market leader in Point-of-Care diagnostic tests for the detection of known, new and emerging infections and inflammatory conditions as well as chemical warfare and bio-terrorism agents.

History

Born out of a joint venture between a German bio-tech company and a visionary family of practicing ophthalmologists, Rapid Pathogen Screening (RPS), Inc. emerged as an independent entity in 2004. Initially, the focus of product development was centered on ocular disease states.

In 2006, RPS achieved two major milestones:

• Opened a new, state-of-the art research laboratory in Sarasota, Florida
• Launched its first product, the RPS Adeno Detector^TM

The following year brought the formation of the RPS Technology and Development organization, a group dedicated to securing government contracts. To date, RPS has been awarded multiple contracts for chemical warfare nerve agent detection and continues to expand this area of the business.

Along the way, RPS has secured two technology patents and has several more pending approval. The company's commitment to innovation and quality provides the foundation for future product developments and technology breakthroughs.

Management Structure

An elected Board of Directors and experienced Leadership Team manage the RPS business. The company founders, José Sambursky, MD and his two sons Daniel and Robert (both MDs), continue to serve on the Board of Directors. Dr. Robert Sambursky also serves as Chief Medical Officer of RPS.

The Biotech group operates as Biotech Visioncare for the production and supply of Intraocular Lenses, and as Biotech Ophthalmics, it offers a range of Ophthalmic solutions. With its global presence and goodwill, the company develops and manufactures high quality, innovative ophthalmic surgical and eye care products that address a wide range of eye disorders.

Based in Ahmedabad, India, the company operates from a custom-built facility with advanced CNC machines, under a controlled clean room environment. Research and development activities for eyecare and the ophthalmic surgical business is aimed at enhancing lens implantation through technologically advanced delivery systems and new designs for intraocular lenses.

Biotech is focused on the growth and expansion of its core businesses.

Few of its assets include:

• A portfolio of industry-leading ophthalmic surgical devices and eye care products
• Product marketing through Distribution Network in over 60 countries
• Well equipped manufacturing and research & development facility.

Biotech is one of the largest manufacturers of IOLs in the world, with a production capacity of over 1.5 million IOLs per annum. Biotech Vision Care has to its credit, the successful execution of supplying over 4,50,000 lenses, as a requirement for the Blindness Eradication Program, a Government of India undertaking.

Biotech е един от най-големите производители на вътреочни лещи в света, с производствен капазитет от 1.5 милиона вътреочни лещи на година. Biotech Visioncare на свой ред успешно доставя над 450 000 лещи във връзка с изискване по програма „Премахване на слепотата”, предприета от правителството на Индия.

In addition to the above, Biotech enjoys a major share in the domestic market, and sports a remarkable overseas network as well. The company currently exports its products to 60 countries including those in Europe, South America, the Middle East, North Africa, South-East Asia and the SAARC Nations.

"As manufacturers and exporters of Intraocular Lenses and patented technology in delivery sytems, we are integrating the world of vision with focussed development of ophthalmic surgical products."

Mehul Asnani, Chairman and CEO

The Biotech group operates as Biotech Visioncare for the production and supply of Intraocular Lenses, and as Biotech Ophthalmics, it offers a range of Ophthalmic solutions. With its global presence and goodwill, the company develops and manufactures high quality, innovative ophthalmic surgical and eye care products that address a wide range of eye disorders.

Based in Ahmedabad, India, the company operates from a custom-built facility with advanced CNC machines, under a controlled clean room environment. Research and development activities for eyecare and the ophthalmic surgical business is aimed at enhancing lens implantation through technologically advanced delivery systems and new designs for intraocular lenses.

Biotech is focused on the growth and expansion of its core businesses.

Few of its assets include:

• A portfolio of industry-leading ophthalmic surgical devices and eye care products
• Product marketing through Distribution Network in over 60 countries
• Well equipped manufacturing and research & development facility.

Biotech is one of the largest manufacturers of IOLs in the world, with a production capacity of over 1.5 million IOLs per annum. Biotech Vision Care has to its credit, the successful execution of supplying over 4,50,000 lenses, as a requirement for the Blindness Eradication Program, a Government of India undertaking.

Biotech е един от най-големите производители на вътреочни лещи в света, с производствен капазитет от 1.5 милиона вътреочни лещи на година. Biotech Visioncare на свой ред успешно доставя над 450 000 лещи във връзка с изискване по програма „Премахване на слепотата”, предприета от правителството на Индия.

In addition to the above, Biotech enjoys a major share in the domestic market, and sports a remarkable overseas network as well. The company currently exports its products to 60 countries including those in Europe, South America, the Middle East, North Africa, South-East Asia and the SAARC Nations.

"As manufacturers and exporters of Intraocular Lenses and patented technology in delivery sytems, we are integrating the world of vision with focussed development of ophthalmic surgical products."

Mehul Asnani, Chairman and CEO

Opto Global is an ophthalmic innovator offering an advanced range of precision ophthalmic and optometric equipment through an extensive world wide independent distributor network. Our focus is to deliver early detection and treatment devices for glaucoma, cataract and AMD (Age-related Macular Degeneration), the most common causes of blindness.

We are committed to supporting our distributors in supplying ophthalmologists, optometrists, hospitals and associated health care professionals the latest technology in a competitive price segment. Opto ophthalmic devices are supported in the field by highly qualified and trained technicians.

Ophthalmic Imaging Systems has been the leading provider of ophthalmic imaging and informatics solutions since 1984. The industry-leading OIS Symphony™ and WinStation product lines have delivered the ability to view all of a practice's ophthalmic images and diagnostic reports side-by-side automatically; producing unprecedented gains in both practice efficiency and quality of care.

Dr. Paulo Ferrara, who created Ferrara Ring®, started his research in 1986. In 1993 he obtained the approval for the Ring’s patent. In 1991 he carried out the first implant in humans, becoming the only doctor with 18-year follow-up. His broad experience has been crucial for the improvement and achievement of better long-term results in patients suffering from keratoconus.

In order to meet the demand of its R&D department, Ferrara Ophthalmics Ltda. started collaborating in 2006 with AJL Ophthalmic S.A., a Spanish company focused on improving and creating new products in ocular surgery. This choice was due to our affinity with AJL’s work philosophy, whose aim is not copying technology, but carrying out research and innovation.

All products hold the CE mark, and the company has established a quality management system according to ISO 13485 and ISO 9001:2000.

Ferrara also collaborates with the CSIC (Spanish National Research Council), the most relevant public research body in Spain, and also cooperates with the IOBA (University Institute of Applied Ophthalmology of the University of Valladolid).

Both these collaborations and the incentive given by the Spanish Government in matter of scientific initiatives, were the factors that motivated Ferrara Ophthalmics to establish in Spain and carry out there the research on new materials and the improvement of Ferrara Ring®.